NIH denies petition by US activists seeking to break patents on Genzyme's Fabrazyme

The US National Institutes of Health has denied a request by three US Fabry's disease patients to force the licensing of patents for Genzyme's Fabrazyme (agalsidase beta), which remains in short supply due to the company's manufacturing problems.